Keyword: Horizon Pharma

Repeated drug price hikes have caught plenty of criticism lately, but the attention isn't dissuading everyone.

Payer discounts are likely to grow even if midterm elections revive attacks on the industry—and investors should be worried about that, analysts say.

Biogen boosted the stickers on some of its key MS medications Monday, and the payoff could make up for sales lost to new rivals.

A New Year often rings in higher drug prices, and many top companies marked the occasion just that way this year.

Horizon has faced its share of trouble with formulary placement and specialty pharmacies, and now those woes have spread.

Horizon has thrown more commercial heft behind long-troubled gout med Krystexxa, thanks to promising early results from a tweaked sales pitch.

The newest stop on the film festival circuit is one with entries that are all about rare diseases.

Industry lobbying group PhRMA has cleared its decks of nearly two dozen members as it tries to distance itself from those companies most likely to catch heat over drug pricing practices.

Biogen's Spinraza raised eyebrows for a $750,000 first-year price, but rare disease medications are expensive, period. Check out this list.

Roche CEO Severin Schwan and Novartis chief Joe Jimenez likely won't rank among biopharma's highest-paid this year. But at least they're on par with each other at almost 12M francs each.